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Background: CD133 has been identified as a cancer stem cell marker for pancreatic ductal
adenocarcinoma. Although leucine-rich-repeat-containing G-protein-coupled receptor 5
(LGR5), a marker of intestinal stem cells, has been shown to be on a higher level of the
stem cell hierarchy than CD133, the expression and function of LGR5 in pancreatic cancer
tissue remains unclear. This study investigated tissue expression of LGR5 and CD133 in
resected pancreatic cancer tissue.
Methods: LGR5 and CD133 expression was immunohistochemically examined in 9
patients with pancreatic ductal adenocarcinoma who underwent resection.
Results: LGR5 was expressed in the cytoplasm of pancreatic cancer cells in 4 of 9
cases. CD133 was not detected in cancerous tissue. In non-neoplastic tissue, LGR5 was
expressed in the basolateral membrane of a subset of endocrine cells. Conversely, CD133
was expressed in the apical membrane of small duct cells. Co-localization of LGR5 and
CD133 was not found in either neoplastic or non-neoplastic tissue. LGR5 expression in
pancreatic cancer cells showed no statistically significant correlation with survival after
surgery.
Conclusion: We have demonstrated that LGR5 is expressed in the cytoplasm of
pancreatic adenocarcinoma cells, and the basolateral membrane of a subset of endocrine
cells of the human pancreas. Further investigation is required to clarify any prognostic
significance of LGR5 expression.
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA) is a highly aggressive
disease usually diagnosed in an advanced stage and for which
effective therapies remain lacking. Increasing evidence suggests
that stem cells play a decisive role not only in the generation of
complex multicellular organisms, but also in the development
and progression of tumors (Clevers, 2011). Many tumors have
been shown to harbor a subset of distinct cancer cells that bear
stem cell characteristics, termed cancer stem cells (CSCs). CSCs
are hypothesized to be exclusively responsible for tumor initia-
tion, propagation, and metastasis. In addition, CSCs are thought
to be highly resistant to chemo- and radiotherapy.
To date, several CSC markers of pancreatic cancer cells have
been identified. A highly tumorigenic CD44+CD24+EpCAM+
cell subpopulation, displaying typical stem cell features, could
initiate tumors at low cell numbers, using a xenograft model of
immunocompromised mice for human pancreatic cancer cells (Li
et al., 2007). CD133 (Hermann et al., 2007), aldehyde dehydroge-
nase 1a1 (Jimeno et al., 2009), and c-Met (Li et al., 2011) have
since been identified as other CSC markers of pancreatic cancer
cells.
We have previously demonstrated that corticosteroids induce
regeneration of acinar cells in patients with autoimmune pancre-
atitis (Ko et al., 2010). In that study, we showed that the presence
of CD133-positive ductal cells correlate with the regeneration of
acinar cells, and thus, play an important role in organ regen-
eration. These data indicated that CD133 is a good marker for
pancreatic stem/progenitor cells.
Clevers and colleagues identified Wnt target gene, leucine-
rich-repeat-containing G-protein-coupled receptor 5 (LGR5) as a
marker for the intestinal stem cells from which all cellular linages
of gastrointestinal epithelium are derived (Barker et al., 2007;
Barker and Clevers, 2010). A recent study suggests that LGR5 is
on a higher level of the stem cell hierarchy than CD133 (Snippert
et al., 2009).
We hypothesized that LGR5 is a stem cell marker of
pancreatic cancer cells on a higher level of the stem cell
hierarchy than CD133. However, LGR5 expression and its
function in pancreatic cancer cells remain unclear. The
present study therefore, investigated the tissue expres-
sion of LGR5 and CD133 in resected pancreatic cancer
tissue.
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PATIENTS AND METHODS
PATIENTS
Nine of 109 patients with PDA who had undergone pancreatic
resection at Aichi Cancer Center Hospital between 2005 and 2010
were included in this pilot study to explore a possible impli-
cation of LGR5 for survival. Five patients had a short survival
of 1-year or less, and four survived longer than 3 years. The
study protocol was approved by our institutional review board.
The study was conducted in accordance with the Declaration of
Helsinki.
IMMUNOHISTOCHEMISTRY
Surgically resected tissues were fixed in 10% formalin and
embedded in paraffin. Sections were deparaffinized, permeabi-
lized, and used for immunohistochemistry. Antigen retrieval was
performed by heating in 0.01M citrate buffer (pH 6.0) in a
microwave. The primary antibodies used for immunohistochem-
istry included rabbit polyclonal antibody to LGR5 (ab75732;
Abcam, Cambridge Science Park, UK) and mouse monoclonal
antibody to CD133 (MB9-3G8; Miltenyi Biotec, Germany).
Dilutions for all antibodies followed the manufacturer’s recom-
mendations. Immunoreactions were intensified using Envision
plus reagent (DAKO, Carpinteria, CA). Immunolabeling was
visualized using 3,30-diaminobenzidine (DAB) as substrate
for horseradish peroxidase. Sections were counterstained with
Mayer’s hematoxylin. LGR5 and CD133 immunostaining in the
neoplastic tissue was compared to immunoreactivity in the
non-neoplastic tissue as an internal positive control. When the
non-neoplastic tissue was overstained or understained, immuno-
histochemical staining was repeated to achieve appropriate
status.
STATISTICAL ANALYSIS
Disease-free and overall survival was analyzed using the Kaplan-
Meier method and log-rank analysis. Hazard ratios were esti-
mated using of a Cox proportional- hazards model. All statistical
tests were two-sided, and statistical significance was defined for
values of P < 0.05. JMP version 9.0.3 software (SAS Institute,
Cary, NC) was used for all statistical analyses.
RESULTS
BASELINE CHARACTERISTICS OF RESECTED PATIENTS WITH PDA
Nine patients (4 men, 5 women) were enrolled in this study
(Table 1). Median age was 64 years (range, 44–72 years). Seven
patients underwent pancreaticoduodenectomy and 2 underwent
distal pancreatectomy. Tumor grade according to the World
Health Organization (WHO) classification was Grade 1 in two
patients and Grade 2 in seven patients. The final stage accord-
ing to 7th edition of Union for International Cancer Control
(UICC) classification was stage IIA in one, IIB in six, and IV in
two patients.
EXPRESSION OF CD133 IN PANCREATIC CANCER TISSUE
All pancreatic cancer cells were negative for CD133 (Table 2,
Figure 1A). Conversely, CD133 was expressed at the apical mem-
brane of small pancreatic duct cells in the non-neoplastic tissue
around the cancer tissue (Table 2, Figure 1B).
Table 1 | Baseline characteristics of patients with resected pancreatic
adenocarcinoma.
Case Sex Age Tumor Surgery TNM Stage Tumor
(years) location categories grade
T N M
1 M 64 Tail DP 3 1 1 IV 1
2 F 54 Head PD 3 1 0 IIB 1
3 M 72 Tail DP 3 1 0 IIB 2
4 F 56 Head PD 3 1 0 IIB 2
5 M 44 Head PD 3 1 0 IIB 2
6 M 71 Head PD 3 1 0 IIB 2
7 F 56 Head PD 3 0 0 IIA 2
8 F 67 Head PD 3 1 1 IV 2
9 F 65 Head PD 3 1 0 IIB 2
PD, pancreaticoduodenectomy; DP, distal pancreatectomy.
EXPRESSION OF LGR5 IN PANCREATIC CANCER TISSUE
Next, we investigated expression of LGR5 in resected pancreatic
cancer tissues. In 4 of the 9 cases, LGR5 was weakly positive
in the cytoplasm of pancreatic cancer cells (Table 2, Figure 2A).
LGR5 was strongly positive in the basolateral membrane of a
subset of remaining endocrine cells in non-neoplastic tissue sur-
rounding the pancreatic cancer tissue (Table 2, Figure 2B). On
the other hand, LGR5 was negative in the apical membrane of
the remaining small pancreatic duct cells that were positive for
CD133 (Figure 2B).
CORRELATION OF LGR5 AND PROGNOSIS OF PANCREATIC CANCER
We investigated correlations between LGR5 expression in pancre-
atic cancer cells and survival after surgery. Median overall survival
has not been reached in the LGR5+ group and 10.4 months in
LGR5− group [hazard ratio (HR), 0.52; 95% confidence inter-
val (CI), 0.08–2.99; P = 0.52]. Median disease-free survival has
not been reached in the LGR5+ group and 5.4 months in LGR5−
group (HR, 0.13; 95% CI, 0.04–1.42; P = 0.13) (Table 3).
DISCUSSION
Central to the CSC concept is the observation that not all cells
in tumors are equal. The CSC concept postulates that, similar to
the growth of normal proliferative tissue such as bone marrow,
skin or intestinal epithelium, the growth of tumors is fueled by a
limited number of dedicated stem cells that are capable of self-
renewal (Clevers, 2011). This stem cell hypothesis has recently
been explored in PDA (Hermann et al., 2007; Li et al., 2007, 2011;
Jimeno et al., 2009).
In the present study, CD133 was expressed at the apical mem-
brane of small pancreatic duct cells in the non-neoplastic tissue
around the cancer tissue. These results are consistent with our
previous data. Hermann et al. reported that human pancre-
atic cancer tissue contains CSCs defined by CD133 expression
that are exclusively tumorigenic and highly resistant to standard
chemotherapy (Hermann et al., 2007). They showed that in the
invasive front of pancreatic tumors, a distinct subpopulation of
CD133+CXCR4+ CSCs determined the metastatic phenotype
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Table 2 | Expression of LGR5 and CD133 in pancreatic tissue and survival time.
Case LGR5 CD133 Survival time
Cancer cells Non-cancer cells Cancer cells Non-cancer cells OS (days) Censored DFS (days) Censored
1 + − − − 306 no 221 no
2 − − − − 111 no 36 no
3 + + − − 2081 yes 2081 yes
4 + + − + 247 no 201 no
5 − + − + 1283 no 552 no
6 + − − − 2061 yes 2061 yes
7 − + − + 2081 yes 1522 no
8 − + − − 292 no 163 no
9 − + − + 315 no 102 no
OS, overall survival; DFS, disease free survival.
FIGURE 1 | Expression of CD133 in pancreatic tissue. (A) Pancreatic cancer cells were negative for CD133. (B) CD133 was expressed at the apical
membrane of the small pancreatic duct cells in the non-neoplastic tissue (arrows).
FIGURE 2 | Expression of LGR5 in pancreatic tissue. (A) LGR5 was weakly positive in the cytoplasm of pancreatic cancer cells. (B) LGR5 was strongly
positive in the basolateral membrane of the remaining endocrine cells in non-neoplastic tissue.
of the individual tumor. However, pancreatic cancer cells were
negative for CD133 in our study. One possible explanation for
this discrepancy is the sensitivity of an anti-CD133 antibody. The
results of immunohistochemical analysis can vary in frequency
from antibody to antibody (Sauter et al., 2009). We used clone
MB9-3G8 (Miltenyi Biotec, Germany), which is widely used and
recognized as reliable antibody against CD133 (O’Brien et al.,
2007; Ricci-Vitiani et al., 2007). In our previous study, we used
the same antibody and showed clear immunostaining in the pan-
creas tissue (Ko et al., 2010). The present results are consistent
with our previous study. Another explanation could be the con-
dition of formalin-fixed tissues, because immunohistochemical
positivity depends on the methods and times of tissue fixation
(Sauter et al., 2009).
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Table 3 | Correlation between LGR5 expression and survival.
LGR5 expression
(−) (+)
n = 5 n = 4
Median OS 10.4 not reached
HR (95% CI) 0.52 (0.08− 2.99, P = 0.52)
Median DFS 5.4 not reached
HR (95% CI) 0.13 (0.04− 1.42, P = 0.13)
OS, overall survival; DFS, disease-free survival; HR, hazard ratio; CI, confidence
interval.
Stem cells of the mouse small intestine, colon, and stom-
ach can be identified by the specific expression of LGR5, a G
protein-coupled receptor of unknown function. LGR5+ intestinal
stem cells are long-lived, proliferating continuously and generat-
ing all the cell types present in the gut. The onset of intestinal
tumorigenesis is driven in most cases by activation of Wnt sig-
nal pathways. Mouse LGR5- positive cells give rise to intestinal
tumors with higher efficiency than other intestinal cell popula-
tions upon mutational activation of the Wnt pathway (Barker
et al., 2009). Therefore, LGR5- positive cells are thought to rep-
resent candidates for CSCs of colorectal cancer. Snippert et al.
reported that CD133marks intestinal stem cells, as well as transit-
amplifying progenitors (Snippert et al., 2009). The expression of
LGR5 in pancreatic tissue has not been investigated. The present
study showed that LGR5was expressed in the cytoplasm of some
pancreatic cancer cells. LGR5 was also positive in the basolat-
eral membrane of the remaining endocrine cells surrounding the
pancreatic cancer tissue. Immunoreactivity of LGR5 in endocrine
cells was stronger than that in pancreatic cancer cells. On the
other hand, LGR5 did not co-localize with CD133 in pancreatic
cancer tissue.
Simon et al. recently studied the prevalence, histoanatomical
distribution and tumor biological significance of LGR5 in tumors
of the human gastrointestinal tract (Simon et al., 2012). That
study found that LGR5 expression was positive in all 17 cases
(100%) with PDA tissue and in 12 of 17 cases (71%) in non-
neoplastic tissue. Localization of LGR5 expression was observed
as mainly cytoplasmic, but a sporadic membrane or core mem-
brane accentuated expression occurred. Localization of LGR5 in
pancreatic cancer cells is consistent with our study. However, the
positive rate for LGR5 was higher than in our result (4 of 9,
44%). One possible explanation for this discrepancy is the use of
different antibodies against anti-LGR5. They used anti-LGR5−
antibody generated by themselves, while we used a commercial
polyclonal antibody against LGR5. We have tested reliability of
several antibodies against LGR5 prior to this study. Therefore,
we used ab75732 (Abcam, Cambridge Science Park, UK) as an
antibody against LGR5 in the present study. Immunoreactivity
of LGR5 for endocrine cells was consistent with our previous
study (Ko et al., 2013). Another possible explanation is the dif-
ferences in ethnic background. Although LGR5expression has not
been studied across ethnic groups, proportions of other colorectal
CSC markers vary according to ethnic background (Leavell et al.,
2012).
The CSC hypothesis predicts that stem cells are responsi-
ble for tumor initiation and preferentially drive tumor growth.
Patients with LGR5+ colorectal cancer and gastric cancer report-
edly show shorter survival than patients with LGR5− (Merlos-
Suarez et al., 2011; Simon et al., 2012). On the contrary, using
mouse models of glioma cells, Barrett et al. described that high
expression of ld1 identifies tumor cells with high self-renewal
capacity, while low ld1 expression identifies tumor cells with pro-
liferative potential but low self-renewal capacity (Barrett et al.,
2012). Their results argue against stringent interpretation of the
CSC hypothesis. In our study, hazard ratios for OS and DFS
with LGR5- positive were 0.52 and 0.13, respectively, however,
there were no statistically significant differences. Moreover, stage
distribution varied among LGR5- positive (stage IIB 3, IV 1)
and negative (stage IIA 1, IIB 3, IV 1) groups, because cases
were not matched for stage. Inadequate statistical power with
small sample size (n = 9) and an absence of case-control study
design are limitations of this study. Further studies with ade-
quate statistical power and stage-matched cases are needed to
verify the prognostic implications of LGR5 in pancreatic cancer,
if any.
Wnt signaling plays an important role in the activation of
the mammalian target of rapamycin (mTOR) pathway to stimu-
late intestinal polyp formation (Fujishita et al., 2008). Activation
of the mTOR pathway has also been implicated in the prolif-
eration of pancreatic neuroendocrine tumors. A recent study
suggests that Wnt/β-catenin signaling contributes to the patho-
genesis and growth of neuroendocrine tumors (Kim et al., 2013).
LGR5 was expressed in the basolateral membrane of a sub-
set of endocrine cells of the pancreas in our study. Although
LGR5 function in endocrine cells and neuroendocrine tumor
cells remains unclear, LGR5 might represent a putative stem cell
marker of matured neuroendocrine cells and neuroendocrine
tumor of the pancreas (Ko et al., 2013). Recent study sug-
gests that LGR5 is expressed in the remaining islets and in
ductal cancer cells in cancerous pancreas, therefore, pancreatic
islets beta cells contain cells-of-origin of PDA that express their
unique markers in the PDA tumor cells (Amsterdam et al.,
2013).
In conclusion, we have demonstrated that LGR5 is expressed in
the cytoplasm of pancreatic cancer cells and the basolateral mem-
brane of endocrine cells of the pancreas in patients with PDA.
Further investigations are required to clarify the biological func-
tions of LGR5 and its possible application as a stem cell marker
for pancreatic exocrine and endocrine tumors.
ACKNOWLEDGMENTS
We acknowledge the contribution of Dr Vikram Bhatia, Associate
Professor, Hepatology, Institute of Liver and Biliary Sciences
(ILBS), New Delhi, India for critical review and drafting of the
manuscript. This work was supported in part by JSGE (Japanese
Society of Gastroenterology) Grant-in-Aid for Scientific Research
(to Nobumasa Mizuno, Yasushi Yatabe, Shigeru B. H. Ko, and
Kenji Yamao), and Grants-in-Aid for Cancer Research from the
Ministry of Health, Labour and Welfare of Japan (to Nobumasa
Mizuno), andNational Cancer Center Research andDevelopment
Fund (to Kenji Yamao).
Frontiers in Physiology | Gastrointestinal Sciences September 2013 | Volume 4 | Article 269 | 4
Mizuno et al. LGR5 expression in pancreatic cancer
REFERENCES
Amsterdam, A., Raanan, C., Schreiber,
L., Polin, N., and Givol, D. (2013).
LGR5 and Nanog identify stem
cell signature of pancreas beta cells
which initiate pancreatic cancer.
Biochem. Biophys. Res. Commun.
433, 157–162. doi: 10.1016/j.bbrc.
2013.02.038
Barker, N., and Clevers, H. (2010).
Leucine-rich repeat-containing
G-protein-coupled receptors
as markers of adult stem cells.
Gastroenterology 138, 1681–1696.
doi: 10.1053/j.gastro.2010.03.002
Barker, N., Ridgway, R. A., van Es, J.
H., van de Wetering, M., Begthel,
H., van den Born, M., et al. (2009).
Crypt stem cells as the cells-of-
origin of intestinal cancer. Nature
457, 608–611. doi: 10.1038/nature
07602
Barker, N., van Es, J. H., Kuipers,
J., Kujala, P., van den Born, M.,
Cozijnsen, M., et al. (2007).
Identification of stem cells in small
intestine and colon by marker gene
LGR5. Nature 449, 1003–1007. doi:
10.1038/nature06196
Barrett, L. E., Granot, Z., Coker, C.,
Iavarone, A., Hambardzumyan, D.,
Holland, E. C., et al. (2012). Self-
renewal does not predict tumor
growth potential in mouse models
of high-grade glioma. Cancer Cell
21, 11–24. doi: 10.1016/j.ccr.2011.
11.025
Clevers, H. (2011). The cancer stem
cell: premises, promises and chal-
lenges. Nat. Med. 17, 313–319. doi:
10.1038/nm.2304
Fujishita, T., Aoki, K., Lane, H. A.,
Aoki, M., and Taketo, M. M.
(2008). Inhibition of the mTORC1
pathway suppresses intestinal
polyp formation and reduces
mortality in ApcDelta716 mice.
Proc. Natl. Acad. Sci. U.S.A. 105,
13544–13549. doi: 10.1073/pnas.
0800041105
Hermann, P. C., Huber, S. L., Herrler,
T., Aicher, A., Ellwart, J. W., Guba,
M., et al. (2007). Distinct popula-
tions of cancer stem cells determine
tumor growth and metastatic activ-
ity in human pancreatic cancer. Cell
Stem Cell 1, 313–323. doi: 10.1016/j.
stem.2007.06.002
Jimeno, A., Feldmann, G., Suarez-
Gauthier, A., Rasheed, Z., Solomon,
A., Zou, G. M., et al. (2009). A
direct pancreatic cancer xenograft
model as a platform for cancer stem
cell therapeutic development. Mol.
Cancer Ther. 8, 310–314. doi: 10.
1158/1535-7163.MCT-08-0924
Kim, J. T., Li, J., Jang, E. R., Gulhati,
P., Rychahou, P. G., Napier, D.
L., et al. (2013). Deregulation of
Wnt/beta-catenin signaling through
genetic or epigenetic alterations
in human neuroendocrine tumors.
Carcinogenesis 34, 953–961. doi: 10.
1093/carcin/bgt018
Ko, S. B., Azuma, S., Yokoyama, Y.,
Yamamoto, A., Kyokane, K., Niida,
S., et al. (2013). Inflammation
increases cells expressing ZSCAN4
and progenitor cell markers in
the adult pancreas. Am. J. Physiol.
Gastrointest. Liver Physiol. 304,
G1103–G1116. doi: 10.1152/ajpgi.
00299.2012
Ko, S. B., Mizuno, N., Yatabe, Y.,
Yoshikawa, T., Ishiguro, H.,
Yamamoto, A., et al. (2010).
Corticosteroids correct aberrant
CFTR localization in the duct and
regenerate acinar cells in autoim-
mune pancreatitis. Gastroenterology
138, 1988–1996. doi: 10.1053/j.
gastro.2010.01.001
Leavell, B. J., Van Buren, E., Antaki,
F., Axelrod, B. N., Rambus, M.
A., and Majumdar, A. P. (2012).
Associations between markers of
colorectal cancer stem cells and ade-
nomas among ethnic groups. Dig.
Dis. Sci. 57, 2334–2339. doi: 10.
1007/s10620-012-2195-3
Li, C., Heidt, D. G., Dalerba, P., Burant,
C. F., Zhang, L., Adsay, V., et al.
(2007). Identification of pancre-
atic cancer stem cells. Cancer Res.
67, 1030–1037. doi: 10.1158/0008-
5472.CAN-06-2030
Li, C., Wu, J. J., Hynes, M., Dosch,
J., Sarkar, B., Welling, T. H., et al.
(2011). c-Met is a marker of pan-
creatic cancer stem cells and thera-
peutic target. Gastroenterology 141,
2218–2227 e5. doi: 10.1053/j.gastro.
2011.08.009
Merlos-Suarez, A., Barriga, F. M., Jung,
P., Iglesias, M., Cespedes, M. V.,
Rossell, D., et al. (2011). The intesti-
nal stem cell signature identifies
colorectal cancer stem cells and
predicts disease relapse. Cell Stem
Cell 8, 511–524. doi: 10.1016/j.stem.
2011.02.020
O’Brien, C. A., Pollett, A., Gallinger,
S., and Dick, J. E. (2007). A human
colon cancer cell capable of initiat-
ing tumour growth in immunode-
ficient mice. Nature 445, 106–110.
doi: 10.1038/nature05372
Ricci-Vitiani, L., Lombardi, D. G.,
Pilozzi, E., Biffoni, M., Todaro,
M., Peschle, C., et al. (2007).
Identification and expansion of
human colon-cancer-initiating
cells. Nature 445, 111–115. doi: 10.
1038/nature05384
Sauter, G., Lee, J., Bartlett, J. M.,
Slamon, D. J., and Press, M. F.
(2009). Guidelines for human epi-
dermal growth factor receptor 2
testing: biologic and methodologic
considerations. J. Clin. Oncol. 27,
1323–1333. doi: 10.1200/JCO.2007.
14.8197
Simon, E., Petke, D., Boger, C., Behrens,
H. M., Warneke, V., Ebert, M.,
et al. (2012). The spatial distri-
bution of LGR5+ cells correlates
with gastric cancer progression.
PLoS ONE 7:e35486. doi: 10.1371/
journal.pone.0035486
Snippert, H. J., van Es, J. H., van den
Born, M., Begthel, H., Stange,
D. E., Barker, N., et al. (2009).
Prominin-1/CD133 marks stem
cells and early progenitors in mouse
small intestine. Gastroenterology
136, 2187–2194. doi: 10.1053/j.
gastro.2009.03.002
Conflict of Interest Statement: The
authors declare that the research
was conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 12 July 2013; accepted: 10
September 2013; published online: 26
September 2013.
Citation: Mizuno N, Yatabe Y, Hara K,
Hijioka S, Imaoka H, Shimizu Y, Ko
SBH and Yamao K (2013) Cytoplasmic
expression of LGR5 in pancreatic ade-
nocarcinoma. Front. Physiol. 4:269. doi:
10.3389/fphys.2013.00269
This article was submitted to
Gastrointestinal Sciences, a section
of the journal Frontiers in Physiology.
Copyright © 2013 Mizuno, Yatabe,
Hara, Hijioka, Imaoka, Shimizu, Ko and
Yamao. This is an open-access article dis-
tributed under the terms of the Creative
Commons Attribution License (CC BY).
The use, distribution or reproduction in
other forums is permitted, provided the
original author(s) or licensor are cred-
ited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use, dis-
tribution or reproduction is permitted
which does not comply with these terms.
www.frontiersin.org September 2013 | Volume 4 | Article 269 | 5
